Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal Steps Up Generics Focus By Establishing “Cross-Segment” Team

This article was originally published in The Pink Sheet Daily

Executive Summary

Wholesaler downplays effect of Wal-Mart generics program.

You may also be interested in...



Wal-Mart Generic Rx Program Expansion Underway With Addition Of 12 More States

Retailer plans to continue expanding its $4 generic drug program to as many states as possible.

Cardinal Plans Expanded Role In Generic Rx Sector

The wholesaler will "participate more in the value chain" for generics via partnerships and use of in-house manufacturing capacity. "Don't interpret that to mean we are going to go buy a generic manufacturer now," CEO Walter says.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel